| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT04507204 Details | 2023-07-27 Interventional | 4 | 267 | Methylphenidate Attention Defic… Hyperkinesis Attention-Defic… | (due to administrative reasons not related to efficacy or safety.) - | |||
| NCT04120987 Details | 2023-07-27 Interventional | 4 | 0 | Lifitegrast Ophthalmic Solu… Cataract Dry Eye Syndrom… Inflammation Dry Eye | Administrative - | |||
| NCT03613792 Details | 2023-07-27 Interventional | 4 | 0 | Fentanyl Ketamine Midazolam Remifentanil Bronchoscopy | Change in procedure means limited value for study question - | |||
| NCT03417921 Details | 2023-07-27 Interventional | 1/2 | - | Gemcitabine Paclitaxel Pancreatic Neop… Pancreatic Canc… | We opened another study. - | |||
| NCT02749292 Details | 2023-07-27 Interventional | 4 | 115 | Rituximab Anti-Neutrophil… Vasculitis | Due to the coronavirus disease 2019 (COVID-19) pandemic and the deleterious impact of rituximab
on vaccination efficacy, the trial was concluded before reaching the target enrollment of 200. The trial has several limitations: It was open-label. it only enrolled patients on continuous B cell depletion for a minimum of 2 years it took place in a single center. | |||
| NCT05119439 Details | 2023-07-25 Interventional | 4 | 23 | Mifepristone Misoprostol Medical Abortio… | Enrollment - | |||
| NCT04334629 Details | 2023-07-25 Interventional | 4 | 0 | Ibuprofen Respiratory Dis… Respiratory Dis… Severe Acute Re… Coronavirus SARS-CoV Infect… | Study withdrawn. - | |||
| NCT03669133 Details | 2023-07-25 Interventional | 2 | 3 | Vitamin E Fatty Liver Non-alcoholic F… HIV Infections NAFLD NASH - Nonalcoh… | lack of coordinator resources and lack of access to study resources during and due to the COVID
pandemic - | |||
| NCT02663518 Details | 2023-07-25 Interventional | 1 | 250 | Immunoglobulin … Nivolumab Rituximab Hematologic Neo… Neoplasms Hematologic Mal… Solid Tumor | Pfizer decided terminating study for administrative reasons on 22Mar2022 (stopping enrollment
as of 15Apr2022). The decision wasn't due to safety concerns or requests from regulatory
authorities. - | |||
| NCT05809895 2022-503099-99 Details | 2023-07-24 Interventional | 2 | 0 | Albumin-Bound P… Carboplatin Gemcitabine Paclitaxel Pembrolizumab Tislelizumab Breast Neoplasm… Triple Negative… Triple Negative… | Business decision, not driven by safety concerns; no new safety signals have been observed in
the ociperlimab program. - | |||
| NCT05791097 2022-503098-12 Details | 2023-07-24 Interventional | 3 | 0 | Albumin-Bound P… Carboplatin Paclitaxel Pembrolizumab Pemetrexed Tislelizumab Carcinoma, Non-… Lung Neoplasms Non-small Cell … | Business decision, not driven by safety concerns; no new safety signals have been observed in
the ociperlimab program. - | |||
| NCT05338658 Details | 2023-07-24 Interventional | 1 | - | Pembrolizumab Neoplasm Metast… Neoplasms Metastasis Solid Tumor | Pending final IP - | |||
| NCT05074433 2021-005222-14 Details | 2023-07-24 Interventional | 3 | 66 | Casirivimab and… COVID-19 Immunocompromis… | Emerging SARS-CoV2 variants impacting susceptibility to study drug - | |||
| NCT04016805 Details | 2023-07-24 Interventional | 2 | 41 | Acalabrutinib Ibrutinib Venetoclax Leukemia Leukemia, Lymph… Leukemia, Lymph… Chronic Lymphoc… | Strategic/Business decision Due to sponsor's business decision, the clinical trial was terminated by the sponsor prematurely. No analysis was done at the termination of the trial, therefore, outcome, and safety data are not available and the numbers of participants analyzed are reported as "0". | |||
| NCT03338920 Details | 2023-07-24 Interventional | 3 | 159 | Sumatriptan Migraine Disord… Acute Migraine … | eDiary data collected not sufficient to utilize in the analysis of protocol endpoints - | |||
| NCT02710396 Details | 2023-07-24 Interventional | 2 | 19 | Carboplatin Paclitaxel Pembrolizumab Pemetrexed Carcinoma Carcinoma, Non-… | Frontline pembrolizumab approved in NSCLC as monotherapy and in combination with chemotherapy
representing a new standard of care. - | |||
| NCT04964843 Details | 2023-07-21 Interventional | 2 | 0 | Acetylcysteine N-monoacetylcys… Alcohol Drinkin… Alcoholism Alcohol Use Dis… | Null results were posted from a neurometabolite study and a recent trial for AUD. Study may
resume if more positive data emerge. - | |||
| NCT04860518 Details | 2023-07-21 Interventional | 2 | 7 | Dexamethasone COVID-19 Covid19 | The decision is based on changes in the pandemic and further weakening of the recruitment that
will not enable a completion of the study in any reasonable time No formal statistical hypotheses were analysed due the early termination of the study with only 5 dosed subjects. | |||
| NCT04407442 Details | 2023-07-21 Interventional | 2 | 5 | Azacitidine BB 1101 Daratumumab Dexamethasone Dexamethasone a… Ichthammol Multiple Myelom… Neoplasms, Plas… Recurrent Plasm… Refractory Plas… | Slow enrollment and change in sponsor direction - | |||
| NCT03336242 Details | 2023-07-21 Interventional | 2 | 20 | Cannabidiol Epilepsy, Absen… Seizures Childhood Absen… | More patients in Cohort 1 than Cohort 2 demonstrated a clinically meaningful reduction of
seizure count. Given this, enrollment of Cohort 3 was discontinued. This study was prematurely terminated by the Sponsor. Enrollment of Cohort 3 was discontinued. |